摘要:Clinical research is challenging.Recent recognition of the hurdles in translating discoveries in the laboratory into new medical treatments has galvanised stakeholders to co-ordinate their efforts to address the problems.In the UK,this has manifested itself as a major capital investment in infrastructure and the direction of research funds from government and charities into training researchers in experimental medicine and sponsoring strategic programmes of translational research.Support for collaborative programmes that enable deep-phenotyping of rare diseases,the development of biobanks for biomarker research and milestone-driven bench-to-bedside project grants are key examples of the new strategy.Imperial College London has been a beneficiary of the investment in translational medicine and provides here a snapshot of the developments and successes that have arisen and the prospects for the future.
